Equities

Pharma Equity Group A/S

Pharma Equity Group A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)0.157
  • Today's Change-0.001 / -0.32%
  • Shares traded11.99k
  • 1 Year change-67.29%
  • Beta1.0944
Data delayed at least 15 minutes, as of Nov 22 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of DKK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4.230.180
Total Receivables, Net630.140.14
Total Inventory------
Prepaid expenses0.42----
Other current assets, total--710.01
Total current assets67710.15
Property, plant & equipment, net0.06----
Goodwill, net------
Intangibles, net14----
Long term investments------
Note receivable - long term--064
Other long term assets0.00----
Total assets817164
LIABILITIES
Accounts payable102.190.65
Accrued expenses------
Notes payable/short-term debt4.095.053.31
Current portion long-term debt/capital leases0.22189.04
Other current liabilities, total2001.50
Total current liabilities342514
Total long term debt8.0706.58
Total debt122319
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities422521
SHAREHOLDERS EQUITY
Common stock1,0231919
Additional paid-in capital------
Retained earnings (accumulated deficit)--2724
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(984)----
Total equity394643
Total liabilities & shareholders' equity817164
Total common shares outstanding1,0233333
Treasury shares - common primary issue0.0100.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.